Agenus, Inc., has announced a licensing agreement with Integrated BioTherapeutics, Inc., to use the QS-21 Stimulon® adjuvant to develop a vaccine against the Ebola and Marburg viruses.
Tag Archives: Marburg
Researchers from Texas Biomed, the Georgia Institute of Technology and Emory University were recently awarded $5.4 million by the U.S. government to develop an experimental vaccine for use against the Ebola and Marburg hemorrhagic viruses.
Paragon Bioservices announced this week that it has been awarded $4.99 million dollars by the U.S. Army to assist the USAMRIID in developing vaccines against such diseases as Ebola Sudan, Ebola Zaire and Marburg virus.
These viruses are considered bioterror threats as they can be spread through aerosol methods.